Vanderbilt Ingram Cancer Center Archive — Page 13 of 48
-
December 17, 2020
Study reveals distinct genomic landscape for young adults with appendiceal cancer
The first study to compare molecular landscapes of early-onset and late-onset appendiceal cancer has revealed distinct non-silent mutations in the tumors of younger patients, setting the stage for the development of potential therapeutic advances for this rare disease. -
November 23, 2020
NCI director urges action to address delayed cancer diagnoses
Delayed cancer diagnoses and treatment due to concerns about potential coronavirus exposure will lead to collateral deaths beyond the pandemic, National Cancer Institute (NCI) Director Ned Sharpless, MD, said Thursday during a virtual visit at Vanderbilt University Medical Center. -
November 23, 2020
Hot spots identified for colorectal cancer mortality rates among young women
Women diagnosed with early-onset colorectal cancer have a greater risk of dying from the disease depending upon their county of residence, according to a study published in Clinical and Translational Gastroenterology. -
November 18, 2020
V Scholar Award to support Byndloss’ cancer research
Mariana Byndloss, DVM, PhD, assistant professor of Pathology, Microbiology and Immunology, has received a V Scholar Award to support her studies of the links between obesity, the gut microbiome and colorectal cancer. -
November 12, 2020
Breast cancer treatment in older women
A new study from Vanderbilt epidemiologists suggests that it’s time to reconsider clinical practice guidelines for the treatment of early-stage breast cancer in older women. -
November 10, 2020
Study underscores importance of personalized medicine in kidney cancer
A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions. -
October 29, 2020
Rini to lead NCI study of COVID-19 in cancer patients
Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.